The final OS analysis of PAPILLON did not reach statistical significance in the ITT population, but a pre-specified crossover-adjusted analysis showed a 43% reduction in the risk of death.
News|Videos|January 9, 2025
Real-World Head-to-Head Analyses Comparing Different Treatment Options For metastatic Castration-Sensitive Prostate Cancer
Sponsored Content: Benjamin H. Lowentritt, MD, FACS reviews Real-World Head-to-Head Analyses Comparing Different Treatment Options For metastatic Castration-Sensitive Prostate Cancer
Advertisement
This educational activity is brought to you by Janssen Biotech, Inc., and is not certified for continuing medical education. The consultant has been paid an honorarium by Janssen Biotech, Inc. The speaker is presenting on behalf of Janssen and must present information in compliance with the U.S. Food and Drug Administration (FDA) requirements applicable to Janssen.
Advertisement
Related to this article
An exploratory landmark analysis of the phase 3 ADAURA trial showed 8-year OS rates of 79% versuss 64% with placebo, with benefit maintained across stages and subgroups.
Frontline zidesamtinib produced a 94% response rate and 100% intracranial response rate in TKI-naive ROS1-positive advanced NSCLC.
First-line trastuzumab deruxtecan reduced the risk of progression or death by 37% compared with pembrolizumab plus chemotherapy in HER2-mutant non–small cell lung cancer.
Edgardo S. Santos Castillero, MD, discusses MAVERICK, B7-H3 ADC data, and tarlatamab sequencing in SCLC, plus molecular testing in a value-based practice.
Adding intercalated gefitinib to adjuvant chemotherapy improved DFS vs chemotherapy alone in completely resected stage II-IIIB EGFR-mutant NSCLC in a phase 3 trial.
The top 5 OncLive TV videos of the week cover insights in polycythemia vera, myelodysplastic syndrome, myelofibrosis, and acute myeloid leukemia.
A real-world study found just one-third of patients remained on adjuvant osimertinib at 3 years, with early discontinuation linked to worse disease-free survival.
Advertisement
Advertisement
Trending on OncLive
1
Ris-Rez Extends Median OS to 18.5 Months vs Topotecan in Relapsed SCLC
2
Tam-Peli Reduces Risk of Death by 54% vs Topotecan in Relapsed SCLC
3
Early Discontinuation of Adjuvant Osimertinib Doubles Recurrence Risk in EGFR-Mutated NSCLC
4
DESTINY-Lung04 Showcases PFS Benefit With First-Line T-DXd in HER2-Mutant NSCLC
5